医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Microba Appoints Therapeutics Head

2022年04月06日 AM10:04
このエントリーをはてなブックマークに追加


 

BRISBANE, Australia

Microba Life Sciences Limited (ASX: MAP) (“Microba” or the “Company”) is pleased to announce Professor Trent Munro will be joining the company as Senior Vice President of Therapeutics. Professor Munro has over 25 years’ research and development experience, including with multinational biopharmaceutical company Amgen.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220405006299/en/

Professor Trent Munro, Senior Vice President of Therapeutics, Microba Life Sciences (Photo: Business Wire)

Professor Trent Munro, Senior Vice President of Therapeutics, Microba Life Sciences (Photo: Business Wire)

Commenting on the appointment, Chief Executive Officer Dr Luke Reid said, “As the company enters into clinical trials, Professor Munro brings significant pharmaceutical and US drug development experience to advance our therapeutic programs and establish partnerships with large pharmaceutical companies.”

Professor Trent Munro commences employment with Microba today, Wednesday, April 6, and will be leading the Company’s therapeutic strategy to progress its valuable drug development programs and pharma partnering engagements.

About Prof Trent Munro

Professor Munro was based in California with Amgen for over six years, including in the role of Executive Director leading a global team. During this time, he played key roles in the translation of molecules from research, through clinical trials, regulatory approval, and global licensure. This included a diverse range of programs spanning novel biologics, small molecules, nucleic acid-based, cell-based and gene-based therapies across multiple therapeutic areas.

In the last two years Professor Munro has held several leadership roles in Australia including Director of the National Biologics Facility (NBF), Program Director of the CEPI funded Rapid Response Vaccine pipeline, Director of the ARC Centre for Biopharmaceutical Innovation (CBI) and Senior Group Leader at the Australian Institute for Bioengineering and Nanotechnology (AIBN) at the University of Queensland.

Professor Munro completed postdoctoral studies in cell biology and developmental genetics at Harvard Medical School and the University of Cambridge and has a PhD in Protein Biochemistry from the University of Queensland.

This announcement has been authorised for release by the Board.

About Microba Life Sciences Limited

Microba Life Sciences is a precision microbiome company driven to improve human health. With world-leading technology for measuring the human gut microbiome, Microba is driving the discovery and development of novel therapeutics for major chronic diseases and delivering gut microbiome testing services globally to researchers, clinicians, and consumers. Through partnerships with leading organisations, Microba is powering the discovery of new relationships between the microbiome, health and disease for the development of new health solutions.

For more information visit: www.microba.com

Microba encourages all current investors to go paperless by registering their details with the designated registry service provider, Automic Group.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220405006299/en/

CONTACT

Dr Luke Reid

Chief Executive Officer

Luke.Reid@microba.com

Simon Hinsley

Investor / Media Relations

simon@nwrcommunications.com.au

+61 401 809 653

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • Nerviano Medical Sciences S.r.l.宣布与默克达成包含许可选择权的合作协议
  • CANbridge Pharmaceuticals Data on CAN106 to be Presented at Two Conferences
  • Where is China’s Global Fund Pledge? Asks AHF
  • United Kingdom National Institute for Health and Care Excellence (NICE) Publishes Interventional Procedure Guidance (IPG) for ReActiv8® Restorative Neurostimulation™
  • ブラッド・キャンサー・ディスカバリー誌の論文が患者転帰を改善するエクセンシアのAI精密医療プラットフォームの能力をさらに裏付け